Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker CHRN
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | SCHEDULE 13D/A (amended) | CHRN ChronoScale Holdings Corporation | Applied Digital Corporation | 139.53M | 96.1% | SCHEDULE 13D/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Steven Boyd | 187,151 | 5.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Armistice Capital, LLC | 187,151 | 5.0% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Mink Brook Asset Management LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | William Mueller | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Mink Brook Capital GP LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Mink Brook Partners LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 12, 2026 | SCHEDULE 13D | CHRN ChronoScale Holdings Corporation | Applied Digital Corporation | 139.53M | 97.5% | SCHEDULE 13D ↗ |
| Apr 9, 2026 | SCHEDULE 13G | CHRN ChronoScale Holdings Corporation | Mink Brook Asset Management LLC | 190,596 | 5.4% | SCHEDULE 13G ↗ |
| Apr 9, 2026 | SCHEDULE 13G | CHRN ChronoScale Holdings Corporation | William Mueller | 190,596 | 5.4% | SCHEDULE 13G ↗ |
| Apr 9, 2026 | SCHEDULE 13G | CHRN ChronoScale Holdings Corporation | Mink Brook Capital GP LLC | 190,596 | 5.4% | SCHEDULE 13G ↗ |
| Apr 9, 2026 | SCHEDULE 13G | CHRN ChronoScale Holdings Corporation | Mink Brook Partners LP | 190,596 | 5.4% | SCHEDULE 13G ↗ |
| Mar 19, 2026 | SCHEDULE 13G | CHRN ChronoScale Holdings Corporation | Cedar Holdings Mgmt LLC | 210,000 | 5.9% | SCHEDULE 13G ↗ |
| Mar 19, 2026 | SCHEDULE 13G | CHRN ChronoScale Holdings Corporation | Keith Kosow | 210,000 | 5.9% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Steven Boyd | 291,146 | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Armistice Capital, LLC | 291,146 | 10.0% | SCHEDULE 13G/A ↗ |
| Jan 29, 2026 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | DBA Trading, LLC | 156,763 | 3.8% | SCHEDULE 13G/A ↗ |
| Jan 29, 2026 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Daniel Asher Descendants Trust | 355,960 | 8.7% | SCHEDULE 13G/A ↗ |
| Jan 29, 2026 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Daniel Asher | 677,723 | 16.5% | SCHEDULE 13G/A ↗ |
| Jan 8, 2026 | SCHEDULE 13G | CHRN ChronoScale Holdings Corporation | DBA Trading, LLC | 0 | 4.6% | SCHEDULE 13G ↗ |
| Jan 8, 2026 | SCHEDULE 13G | CHRN ChronoScale Holdings Corporation | Daniel Asher | 321,763 | 9.5% | SCHEDULE 13G ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Steven Boyd | 289,876 | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Armistice Capital, LLC | 289,876 | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Steven Boyd | 3.00M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Armistice Capital, LLC | 3.00M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Benjamin Natter | 1.00M | 4.6% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Kent Lake Partners LP | 1.00M | 4.6% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Kent Lake PR LLC | 1.00M | 4.6% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Steven Boyd | 2.25M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CHRN ChronoScale Holdings Corporation | Armistice Capital, LLC | 2.25M | 10.0% | SCHEDULE 13G/A ↗ |
30 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:44 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances